Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384536 | 1.00 | MDM2 (0.35) | MDM2GAAL3MBTL1ROCK2ROCK1 | |
| SCHEMBL10198508 | 1.00 | MDM2 (0.35) | MDM2GAAL3MBTL1ROCK2ROCK1 | |
| SCHEMBL18458286 | 0.86 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL16171239 | 0.86 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL2600363 | 0.86 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL681668 | 0.86 | — | — | |
| SCHEMBL23366007 | 0.85 | MDM2 (0.41) | MDM2 | |
| SCHEMBL17827401 | 0.85 | MDM2 (0.41) | MDM2 | |
| SCHEMBL21501958 | 0.85 | MDM2 (0.41) | MDM2 | |
| SCHEMBL27089683 | 0.85 | MDM2 (0.41) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220175785-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC | 2021-06-17 | — | — | US | disclosed |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2020-09-03 | — | — | US | disclosed |
| US-10751342-B2 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MDM2 2449/4885GAA 1422/4885L3MBTL1 1139/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MDM2 2449/4885GAA 1422/4885L3MBTL1 1139/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | MDM2 4545/4885GAA 1808/4885L3MBTL1 1274/4885 |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | MDM2 3317/4885GAA 2688/4885L3MBTL1 760/4885 |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | MDM2 1656/4885GAA 1771/4885L3MBTL1 345/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | MDM2 2264/4885GAA 1444/4885L3MBTL1 1140/4885 |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | MDM2 2964/4885GAA 3013/4885L3MBTL1 1517/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | MDM2 2964/4885GAA 3013/4885L3MBTL1 1517/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | MDM2 1959/4885GAA 1755/4885L3MBTL1 1584/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | MDM2 1781/4885GAA 2763/4885L3MBTL1 1380/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | MDM2 1862/4885GAA 2798/4885L3MBTL1 1340/4885 |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | MDM2 1656/4885GAA 1771/4885L3MBTL1 345/4885 |
| US-20220175785-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | MDM2 2964/4885GAA 3013/4885L3MBTL1 1517/4885 |
| US-10751342-B2 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | BTK, SYK, LYN | MDM2 3019/4885GAA 2903/4885L3MBTL1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.